Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 4/20 | 0.39 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.39 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 5/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.34 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GLB1 | P16278 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22389582 | 1.00 | SLC6A1 (0.39) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL22389581 | 1.00 | SLC6A1 (0.39) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL20660346 | 1.00 | SLC6A1 (0.39) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL3619895 | 0.86 | SLC6A1 (0.39) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL3619898 | 0.86 | SLC6A1 (0.39) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL3619899 | 0.86 | SLC6A1 (0.39) | SLC6A1SLC6A11SLC6A13GABRA5GABRB2 | |
| SCHEMBL3233892 | 0.85 | GBA1 (0.43) | GBA1MAN1B1PYGLGBA2GAA | |
| SCHEMBL3279547 | 0.85 | GBA1 (0.43) | GBA1MAN1B1PYGLGBA2GAA | |
| SCHEMBL3278567 | 0.85 | GBA1 (0.43) | GBA1MAN1B1PYGLGBA2GAA | |
| SCHEMBL3278572 | 0.85 | GBA1 (0.43) | GBA1MAN1B1PYGLGBA2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3654968-B1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11207312-B2 | Metallo-beta-lactamase inhibitors and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200281913-A1 | Metallo-Beta-Lactamase Inhibitors and Methods of Use Thereof | MERCK SHARP & DOHME CORP. (US) | 2020-09-10 | — | — | US | disclosed |
| EP-3654968-A1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | Merck Sharp & Dohme Corp. (US) | 2020-05-27 | — | — | EP | disclosed |
| WO-2019018186-A1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2019-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200281913-A1 | Metallo-Beta-Lactamase Inhibitors and Methods of Use Thereof | MLX, MMP12, SLC11A2 | SLC6A1 350/4885SLC6A11 741/4885SLC6A13 1360/4885 |
| US-11207312-B2 | Metallo-beta-lactamase inhibitors and methods of use thereof | MLX, MMP12, SLC11A2 | SLC6A1 350/4885SLC6A11 741/4885SLC6A13 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.